Novo Nordisk A/S (NYSE:NVO) Shares Sold by Addison Advisors LLC

Addison Advisors LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 15.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,283 shares of the company’s stock after selling 424 shares during the quarter. Addison Advisors LLC’s holdings in Novo Nordisk A/S were worth $196,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Edge Capital Group LLC grew its holdings in shares of Novo Nordisk A/S by 1.1% in the fourth quarter. Edge Capital Group LLC now owns 58,465 shares of the company’s stock valued at $5,029,000 after purchasing an additional 635 shares during the period. Rothschild Investment LLC boosted its holdings in Novo Nordisk A/S by 34.2% in the 4th quarter. Rothschild Investment LLC now owns 122,112 shares of the company’s stock valued at $10,504,000 after purchasing an additional 31,144 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Novo Nordisk A/S by 5.4% in the 4th quarter. IFP Advisors Inc now owns 11,558 shares of the company’s stock valued at $994,000 after buying an additional 594 shares during the period. RPG Investment Advisory LLC increased its holdings in shares of Novo Nordisk A/S by 42.4% during the 4th quarter. RPG Investment Advisory LLC now owns 83,144 shares of the company’s stock worth $7,152,000 after buying an additional 24,758 shares during the last quarter. Finally, Birchcreek Wealth Management LLC raised its position in shares of Novo Nordisk A/S by 76.3% during the 4th quarter. Birchcreek Wealth Management LLC now owns 4,481 shares of the company’s stock valued at $385,000 after buying an additional 1,939 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NVO. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $90.94 on Wednesday. The stock has a market capitalization of $408.07 billion, a price-to-earnings ratio of 27.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The business has a 50-day moving average of $85.32 and a 200 day moving average of $107.42. Novo Nordisk A/S has a 12 month low of $77.82 and a 12 month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s payout ratio is 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.